Beijing Huaguan Biotechnology

Beijing Huaguan Biotechnology Co., Ltd., operating under the brand Chempion, is a vertically integrated biopharmaceutical enterprise established in 2018 with headquarters in Beijing's Haidian District. The company was founded by Dr. Chen Jian, a seasoned professional in the pharmaceutical industry. Dr. Chen holds a doctorate from the Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, and completed postdoctoral studies at the University of Rouen in France. His extensive background includes participation in the establishment of PPDai's Beijing operations and substantial experience in both innovative drug research and development and industrial-scale production, which forms the technical foundation of the company.

Since its inception, the company has undergone significant expansion, establishing a network of four R&D centers in Beijing, Nanjing, Suzhou, and Chongqing. A pivotal milestone was the 2023 acquisition of Inner Mongolia Jingdong Pharmaceutical, which now serves as its GMP-compliant active pharmaceutical ingredient (API) and key starting materials (KSMs) manufacturing base. This strategic growth has been supported by multiple funding rounds, including investments from notable entities such as Tsinghua University's Hotung Health Fund, Zhongguancun Science City Fund, and publicly listed companies like Sihuan Pharmaceutical and Xiamen Kingdomway Group.

The firm's business model is centered on providing comprehensive, integrated services across the entire pharmaceutical value chain, from preclinical research to post-launch supply. Its core operations are built upon three distinct technology platforms: an advanced antibody-drug conjugate (ADC) platform, a complex molecule synthesis platform, and a platform combining continuous flow and enzymatic catalysis technologies. This infrastructure enables the company to serve a diverse clientele, including developers of innovative drugs, generic pharmaceutical manufacturers, and companies in the broader health and wellness sector. Revenue is generated by supplying materials such as APIs and intermediates, as well as offering technical services for drug development and registration. Keywords: pharmaceutical R&D, antibody-drug conjugates, ADC platform, small molecule drugs, continuous flow technology, enzyme catalysis, active pharmaceutical ingredients, API manufacturing, CDMO services, preclinical research, generic drugs, complex molecule synthesis, pharmaceutical industrialization, drug development services, GMP production, specialty chemicals, biopharmaceutical, health products, pharmaceutical outsourcing, clinical supply